Molecules of the Month

July 2021

July’s edition of Small Molecules of the Month, features a selective monovalent estrogen receptor degrader in Ph. III, a remarkable 4(!) neurology clinical candidates from Takeda (including 2 recently licensed by Takeda to Neurocrine, TAK-653 and TAK-041), several oncology clinical candidates including two sulfoximines, and a small molecule that degrades its target via its own ubiquitination. Thanks to our featured reviewers for their feedback, with special thanks to neuroscience reviewer Jake Schwarz for feedback and commentary on an unusual 5 neuroscience molecules this month.


MOTY Nominees

Molecule of the Year

Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >15,000 drug hunters worldwide. Unsubscribe anytime.